WZWei Zhou

Wei Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Zhou has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Hongguang Nie

    Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China

    1 shared publication
  • Tong Yu

    Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China

    1 shared publication
  • Yan Ding

    Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang 110122, China

    1 shared publication
  • Yapeng Hou

    Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China

    1 shared publication
  • Zhenxing Wang

    Department of Hematology and Breast Cancer, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China

    1 shared publication

Latest Publications

  • Mesenchymal Stem Cell Therapy for ALI/ARDS: Therapeutic Potential and Challenges

    by Zhenxing Wang, Tong Yu, Yapeng Hou, Wei Zhou, Yan Ding, Hongguang Nie

    Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a serious clinical common disease, which may be caused by a variety of pathological factors and can induce a series of serious complications. There is still no specific and effective method for the treatment of ALI/ARDS. Mesenchymal stem cells (MSCs) have been one of the treatment methods for ALI, which can regulate related signal pathways such as PI3K/AKT, Wnt, and NF-κB to reduce inflammation. MSCs exist in a variety of tissues and have the ability of self-renewal and differentiation, which can be activated by specific substances or environments and home to the site of tissue damage, where they differentiate into new tissue cells and repair the damage. Both exosomes and cytokines involving the paracrine mechanism of MSCs have benefits on the treatment of ALI. Lung organoids produced by 3D culture technology can simulate the characteristics of the lung and help to research the pathophysiological process of ALI. This review summarizes the mechanisms by which MSCs treat ALI/ARDS and expects to use 3D models for future challenges in this field.